CT-388

all catalysts(0)

nothing on the calendar yet

News(4)

• Roche pours $750M into Oregon manufacturing plant as obesity push expands
  After committing $2 billion to a new North Carolina facility to boost capacity for its next-gen obesity candidates, Roche's Genentech is putting down more cash to expand a device fill-finish site i…
  biospace · 7h ago
• Roche cans one Carmot obesity asset as another shows best-in-class potential
  Acmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…
  biospace · 27d ago
• Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
  Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
  biospace · 28d ago
• ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
  At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
  biopharma_dive · 2mo ago